Novel therapies in development for the treatment of traumatic brain injury

被引:41
作者
Vink, R [1 ]
Nimmo, AJ
机构
[1] Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia
[2] James Cook Univ N Queensland, Sch Pharm & Mol Sci, Townsville, Qld, Australia
基金
英国医学研究理事会;
关键词
cyclosporin A; head injury magnesium; neuropeptides; neuroprotection; neurotrauma; substance P;
D O I
10.1517/13543784.11.10.1375
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In industrialised countries, the mean per capita incidence of traumatic brain injury (TBI) that results in a hospital presentation is 250 per 100,000. In Europe and North America alone, this translates to > 2 million TBI presentations annually. Approximately 25% of these presentations are admitted for hospitalisation. Despite the significance of these figures, there is no single interventional pharmacotherapy that has shown efficacy in the treatment of clinical TBI. This lack of efficacy in clinical trials may be due, in part, to the inherent heterogeneity of the traumatic brain injury population. However, it is the multifactorial nature of secondary injury that also poses a major hurdle, particularly for those therapies that have been designed to specifically target an individual injury factor. It is now becoming increasingly recognised that any successful TBI therapy may have to simultaneously affect multiple injury factors, somewhat analogous to other broad spectrum interventions. Recent efforts in experimental TBI have therefore focussed on developing novel pharmacotherapies that may affect multiple injury factors and thus improve the likelihood of a successful outcome. While a number of interventions are noteworthy in this regard, this review will focus on three novel compounds that show particular promise: magnesium, substance P antagonists and cyclosporin A.
引用
收藏
页码:1375 / 1386
页数:12
相关论文
共 139 条
[1]   Cyclosporin ameliorates traumatic brain-injury-induced alterations of hippocampal synaptic plasticity [J].
Albensi, BC ;
Sullivan, PG ;
Thompson, MB ;
Scheff, SW ;
Mattson, MP .
EXPERIMENTAL NEUROLOGY, 2000, 162 (02) :385-389
[2]   SUBSTANCE-P INCREASES RELEASE OF ACETYLCHOLINE IN THE DORSAL STRIATUM OF FREELY MOVING RATS [J].
ANDERSON, JJ ;
CHASE, TN ;
ENGBER, TM .
BRAIN RESEARCH, 1993, 623 (02) :189-194
[3]  
[Anonymous], MAGNESIUM
[4]  
[Anonymous], MAGNESIUM CELL
[5]  
Bara M., 1984, MAGNESIUM, V3, P212
[6]   Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats [J].
Bareyre, FM ;
Saatman, KE ;
Raghupathi, R ;
McIntosh, TK .
JOURNAL OF NEUROTRAUMA, 2000, 17 (11) :1029-1039
[7]   Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging [J].
Barzo, P ;
Marmarou, A ;
Fatouros, P ;
Hayasaki, K ;
Corwin, F .
JOURNAL OF NEUROSURGERY, 1997, 87 (06) :900-907
[8]  
Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125
[9]   Co-localization of N-methyl-D-aspartate receptors and substance P (neurokinin-1) receptors in rat spinal cord [J].
Benoliel, R ;
Tanaka, M ;
Caudle, RM ;
Iadarola, MJ .
NEUROSCIENCE LETTERS, 2000, 291 (02) :61-64
[10]   Selective blockade of substance P or neurokinin a receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat [J].
Bereiter, DA ;
Bereiter, DF ;
Tonnessen, BH ;
Maclean, DB .
NEUROSCIENCE, 1998, 83 (02) :525-534